HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regenerationElias Papatheodorou moves from Chair of the Board to CEO of...

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, researchers from the Mayo Clinic in Rochester (USA) and HepaRegeniXHRX-215 proved to be safe and...